Nomi Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 34)
Nomi Health logo

Nomi Health

EmergingHealthTech

Employer Health Benefits

Nomi Health provides self-insured employers a direct primary care and benefits platform with transparent pricing, bypassing traditional insurance middlemen to reduce total healthcare spend.

AI VisibilityBeta
Overall Score
D34
Category Rank
#577 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
33
Perplexity
38
Gemini
30

About

Nomi Health operates a direct-to-employer healthcare model that contracts directly with care providers — primary care clinics, labs, imaging centers, and specialists — to offer self-insured employers transparent, pre-negotiated prices without insurance company intermediaries. The platform combines a provider network, benefits administration technology, and care navigation to give employers full visibility into what they are spending and why, replacing opaque managed care contracts with itemized, market-rate pricing.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

34
Overall Score
90
#577
Category Rank
#2
80
AI Consensus
83
stable
Trend
stable
33
ChatGPT
92
38
Perplexity
93
30
Gemini
89
35
Claude
96
37
Grok
95

Key Details

Category
Employer Health Benefits
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Nomi Health
Employer Health Benefits

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.